Genmab shares slide on FDA delay

Asking for more time to review chemistry and manufacturing data, the FDA pushed back its deadline to make a decision on the leukemia drug Arzerra by three months. The news cost Genmab about seven percent of its share price. Genmab and its partner, GlaxoSmithKline, are seeking an accelerated approval based on data from a small trial with no comparison arm. The FDA now has until October 31 to decide if the drug warrants an approval. Release | Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.